Theralase Technologies Inc. V.TLT

RE:The Key to Theralase ACT

[ScienceFirst]

Two 2014 articles that are still of actuality.  And back-then assumptions have proven right so far.

Theralase CEO Roger White talks to Cantech Letter

 

Can you explain why your PDCs are safer and more effective than other FDA approved Photo Dynamic Compounds?

The Theralase PDCs are safer and more effective than other FDA approved Photo Dynamic Compounds for a number of reasons. First, they are small molecule targeted drugs that are able to localize to the nucleus of a cancer cell. Most targeted drugs today are either small molecule drugs or what is known as monoclonal antibodies. Small molecule drugs diffuse into cells and can act on targets that are found inside the cell. Monoclonal antibodies cannot penetrate the cell’s plasma membrane and are directed against targets that are on the cell surface. Because the Theralase PDCs are small molecules they can enter any cancer cell and are not as limited in scope as monoclonal antibodies, which require a specific marker or protein sequence on the outside of the cell to localize. The two current FDA approved drugs (Aminolevulinic Acid HCL (5-ALA) and Photofrin®) are also small molecules, but their target is the mitochondria of the cell. The number of mitochondria in a cell varies widely by organism and tissue type, with some cells having only a single mitochondrion and others having several thousand mitochondria. Because cancer cells may have multiple mitochondria versus one nucleus a much greater amount of PDC would be required to destroy the cell versus the Theralase PDCs; hence the toxicity of the Theralase PDCs would be substantially reduced and the efficacy significantly enhanced over ALA and Photofrin®.

 

How does mice data translate to human data?

If you are investigating monoclonal antibodies, then I believe that mouse data would not translate well to human data as different mammalian cells (mouse versus human, for example) would have different markers on the cancer cell surface. However, if you are investigating small molecules that enter a cancer cell, then I believe that mouse data would translate extremely well to human data in the sense that all eurkaryotes (mammalian cells) have almost identical cells and associated organelles, except for minor differences in DNA coding attributable to variations in species.Therefore, the strong and successful pre-clinical data collected by Theralase on mouse data should translate extremely well to human clinical testing.

 

What proof do you have that your cancer therapy will work in humans?

None, as it has never been testing in a human clinical model; however, based on the nuclear acting small molecule PDCs that Theralase has patented, all indications support the hypothesis that it will work as effectively in humans as it has on mice.

 

Theralase Technologies Inc. Upends Cancer Research with Immune System Response | Midas Letter